FDA Approves First Gene Therapy to Restore Hearing

Children who were born unable to hear are now dancing to music and responding to whispers, thanks to a revolutionary gene therapy that just received FDA approval.

Regeneron's Otarmeni became the first gene therapy approved to treat genetic hearing loss, marking a historic moment in medicine. The one-time treatment targets a rare condition called OTOF-related hearing loss, which affects about 50 newborns each year in the U.S.

The therapy works by delivering a functional copy of the OTOF gene directly into the inner ear. Without this gene, children lack a protein called otoferlin that allows sound signals to travel from the ear to the brain, leaving them with severe to profound hearing loss even though their ear structures are perfectly intact.

In the pivotal CHORD trial, the results stunned researchers. Eighty percent of participants achieved hearing levels that met the primary success measure within 24 weeks, and with longer follow-up, 42 percent reached completely normal hearing that included the ability to hear whispers.

Dr. Eliot Shearer, a trial investigator at Boston Children's Hospital, described watching his young patient respond to their mother's voice for the first time. These children can now interact with the world through natural, 24/7 hearing without depending on devices for the rest of their lives.

The treatment involves a single dose delivered through infusion directly into the cochlea. Participants ranged from 10 months to 16 years old, and the therapy worked in both one and two ear treatments.

Perhaps most remarkably, Regeneron announced it will provide Otarmeni completely free to all eligible patients in the United States. This unprecedented move makes the therapy accessible regardless of insurance status or ability to pay.

The Ripple Effect

This approval represents more than just restored hearing for 50 children per year. It proves that gene therapy can restore a neurosensory function to completely normal levels, something never before achieved by the FDA.

The success opens doors for treating other genetic sensory conditions that were previously considered permanent. Researchers now have a roadmap for developing gene therapies that don't just manage symptoms but actually restore normal function.

For families navigating genetic hearing loss, this adds a powerful new option alongside sign language, hearing aids, cochlear implants, and other communication approaches. Parents can now choose the path that best fits their family's unique needs and values.

The therapy showcases what's possible when scientific innovation meets compassionate access, proving that breakthrough medicine can reach everyone who needs it.